EP300 and colorectal carcinoma: Therefore, future in vivo studies should be directed toward evaluating combinatory treatments of HDACis with modulators of CBP/p300 signaling in mouse models of CRC to determine whether tumor/size incidence is reduced compared with treatment with each class of agent in isolation.